Syros Pharma's lead candidate fails to impress in mid-stage blood cancer study; shares down 48% premarket [Seeking Alpha]
Syros Pharmaceuticals, Inc. (SYRS)
Last syros pharmaceuticals, inc. earnings: 3/5 06:57 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.syros.com
Company Research
Source: Seeking Alpha
Syros Pharma's lead candidate fails to impress in mid-stage blood cancer study; shares down 48% premarketThinly traded micro cap Syros Pharmaceuticals (NASDAQ:SYRS) slumps48% premarket on increased volume in response topreliminary data from a Phase 2 clinical trial assessing lead candidate SY-1425 (tamibarotene) in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The results were presented as ASH in Atlanta, GA.Out of 48 evaluable patients (23 with AML and 25 with MDS), there was only one complete responder. 10 AML and two MDS patients showed "evidence of clinical activity."On the safety front, most adverse events (AEs) were mild or moderate. The most common Grade 3 (serious) or Grade 4 (life-threatening) AE was abnormally high blood triglycerides (16%).Development is ongoing.Tamibarotene is a selective retinoic acid receptor alpha agonist.See all stocks on the move »
Show less
Read more
Impact Snapshot
Event Time:
SYRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRS alerts
High impacting Syros Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SYRS
News
- Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML [Yahoo! Finance]Yahoo! Finance
- Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock? [Yahoo! Finance]Yahoo! Finance
- Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression [Yahoo! Finance]Yahoo! Finance
- Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpressionBusiness Wire
SYRS
Earnings
- 3/27/24 - Miss
SYRS
Analyst Actions
- 4/1/24 - HC Wainwright
SYRS
Sec Filings
- 4/12/24 - Form PRE
- 4/5/24 - Form 4
- 4/3/24 - Form 144
- SYRS's page on the SEC website